Core Findings - The study confirms that the GLP-1/GIP dual receptor agonist Tirzepatide effectively reduces muscle fat deposition in type 2 diabetes patients while maintaining reasonable muscle mass changes [4][5] - After 52 weeks of treatment, patients showed significant weight loss and improved muscle fat infiltration, with muscle mass changes scientifically aligned with weight loss [4][5] - The research utilized data from the UK Biobank, involving nearly 3,000 real-world cases, providing a precise reference for clinical outcomes [4] Research Background - This milestone study originated from the MRI subgroup analysis of the SURPASS-3 clinical trial and was published in The Lancet Diabetes & Endocrinology in June 2025 [5] - The research team employed high-precision MRI technology to systematically compare the effects of Tirzepatide and insulin degludec on muscle volume and fat infiltration in type 2 diabetes patients [5][7] Clinical Significance - Weight management is a core strategy in type 2 diabetes treatment, with over 10% weight loss potentially leading to disease remission and cardiovascular benefits [7] - Traditional weight loss methods often result in muscle loss, increasing the risk of sarcopenia in elderly patients [7] - Tirzepatide, as the first GIP/GLP-1 dual receptor agonist, has demonstrated superior weight loss and fat control effects, with this study providing authoritative data on its impact on muscle composition [7][8] Research Methodology - The study employed an international multicenter, randomized controlled trial design, including strictly defined type 2 diabetes patients [8] - Participants were divided into four groups: Tirzepatide 5mg/10mg/15mg weekly injection groups and a daily injection control group of insulin degludec [8] Research Highlights - Precise imaging assessments were conducted at baseline and after 52 weeks using MRI to quantify thigh muscle fat infiltration and muscle volume [9] - The introduction of UK Biobank data established a muscle-weight change model, enhancing the generalizability of the results [9] - Key findings indicated that weight loss does not equate to muscle loss, showcasing Tirzepatide's unique advantages [9][10] Clinical Breakthrough - The study innovatively used MRI technology to assess the dual benefits of weight loss and muscle quality optimization in diabetes treatment [13] - Tirzepatide achieved significant weight loss (average 10.1%) while effectively reducing muscle fat infiltration, with muscle mass decrease within physiological adaptation limits [13][15] Multiple Clinical Benefits - Tirzepatide demonstrated a unique "fat loss, muscle preservation" advantage, significantly lowering muscle fat infiltration by 0.36 percentage points [15] - The muscle volume decrease of 0.64 liters was proportionate to weight loss, outperforming muscle loss from simple dieting [15] - The study provides critical decision-making references for clinicians, especially for patients needing enhanced weight management [15] Limitations and Future Directions - The study did not assess changes in muscle strength and daily activity capabilities [15] - There was a lack of strict control over lifestyle factors such as diet and exercise [15] - Long-term efficacy and safety beyond one year require further validation [15] - The research lays the groundwork for future exploration of drug-exercise combined interventions and tailored treatment strategies for specific populations [15]

肥胖世界ObesityWorld . 《肥胖世界》Obesity World - 同步传真肥胖及代谢国际新学术进展，为医学减重临床、教研人员搭建一座与国际接轨的桥梁，「每医健」旗下内容平台。 以下文章来源于肥胖世界ObesityWorld ，作者肥胖世界 全球已有超10亿人被肥胖困扰。许多人以为"胖"仅是外表问题，殊不知腹部脂肪的异常实际上是代谢疾病的"隐形杀手"——它悄然引发胰岛素 抵抗、糖尿病、心血管疾病，甚至提高癌症风险。令人惊奇的是，减重能迅速扭转这些健康危机：血糖平稳了、血压下降了、血管恢复弹性 了。但科学界一直未能破解这一谜团：脂肪组织内部到底经历了什么变化？是细胞数量减少了？还是基因表达重新"洗牌"了？ 为揭开这一谜团，伦敦帝国理工学院的Tricia Tan和William R. Scott领导的研究团队运用单细胞核测序技术分析了70人超过17万个脂肪细胞， 并结合前沿空间转录组学，首次绘制了肥胖状态下脂肪组织的"病变地图"，以及减重如何让它实现"凤凰涅槃"。 一、脂肪组织重塑全景图 研究团队构建了迄今最全面的脂肪组织单细胞图谱，涵盖171,247个细胞，样本来自25名极度肥胖者（术前及减重后） ...

Core Viewpoint - Semaglutide, a drug for treating type 2 diabetes and long-term weight management, is recognized for its effective blood sugar reduction and rapid weight loss, leading to its popularity as a "weight loss miracle drug" [4]. Group 1: Mechanism of GLP-1 - The human body can produce a natural version of these drugs, known as GLP-1, which is influenced by specific gut bacteria that convert indigestible food components into appetite-reducing hormones [6]. - GLP-1 and other hormones like PYY help regulate blood sugar through the pancreas and signal the brain about satiety, slowing down food movement in the digestive tract [6]. Group 2: Foods that Promote Natural GLP-1 Production - Eggs are rich in protein and monounsaturated fats, which can enhance GLP-1 secretion, leading to lower post-meal blood sugar levels and reduced hunger [8]. - Nuts such as almonds, pistachios, and peanuts may increase GLP-1 levels due to their protein, fiber, and healthy fat content, which also aids in insulin sensitivity [8]. - High-fiber grains like oats, barley, and whole wheat can stimulate GLP-1 release by slowing digestion and producing short-chain fatty acids through fermentation [9]. - Avocados, due to their high fiber and monounsaturated fat content, can also boost GLP-1 levels and improve overall meal satisfaction [10]. - Olive oil, rich in unsaturated fats, has been shown to enhance GLP-1 release compared to saturated fats, improving insulin sensitivity and lowering blood sugar levels [10]. - Vegetables such as Brussels sprouts, broccoli, and carrots are beneficial for regulating blood sugar and may positively influence GLP-1 levels [10]. Group 3: Lifestyle Factors - A healthy lifestyle, including regular exercise, stress management, sleep, outdoor activities, and a balanced diet, is crucial for managing metabolic diseases and overall health [11]. - Incorporating minimally processed foods rich in fiber and polyphenols can significantly support metabolic health and appetite control [11]. Group 4: Potential Side Effects of GLP-1 Drugs - While GLP-1 drugs can be effective for weight loss, they may have side effects such as nausea, vomiting, diarrhea, abdominal pain, and dizziness [12].

整理 | GLP1减重宝典内容团队 自去年尼马昔单抗在一项中期研究中失败后，Skye 停止了其眼部疾病候选药物的开发，此后该公司一直寄希望于尼马昔单抗（一种每 周皮下注射的药物）来推动增长。 尼马昔单抗旨在阻断有助于分解储存脂肪和调节食欲相关激素的 CB1 蛋白，从而有助于持续减重而不损失肌肉。 Skye Bioscience (SKYE.O) 的实验性疗法在一项中期研究中未能实现显著降低肥胖成年人体重的主要目标，导致其股价周一下跌逾 60%。 接受尼马昔单抗 (nimacimab) 治疗的患者在调整安慰剂率后，体重减轻了 1.26%，低于该公司预期的 5% 至 8%。 "虽然我们仍然对 Skye 靶向 CB1 的方法很感兴趣，但从今天报告的数据来看，我们仍未确信这一点，"Cantor 分析师 Kristen Kluska 表示。她补充说，如果更高的剂量能够带来足够的减重效果，从而具有竞争力，那么这仍是一个"让我看看的故事"。 Skye 表示，在研究中，尼马昔单抗并未观察到与此类药物相关的神经精神问题。 "我们已经找到了一个解决方案，可以解决迄今为止困扰该机制的安全问题，"首席执行官 Punit Dhillo ...

美国西北大学芬伯格医学院和辛普森·奎里表观遗传学研究所在10月3日宣布，杰出生物化学家、纽约洛克菲勒大学Lulu Chow Wang和 Robin Chemers Neustein研究副教授Svetlana Mojsov荣获年度金伯利生物化学与分子遗传学奖，奖金高达25万美元。 整理 | GLP1减重宝典内容团队 Mojsov因发现胰高血糖素样肽1（GLP-1）而获奖。GLP-1是一种由肠道组织产生的肠促胰岛素激素，在胰岛素分泌和葡萄糖代谢中发 挥关键作用。她的研究成果已被广泛应用于糖尿病和减肥治疗。 她将在芝加哥范伯格校区进行公开演讲，与教职员工、研究员和学生见面，并出席2026年春季的颁奖晚宴。 "莫伊索夫博士开创性和变革性的工作遗产证明了她的奉献精神和才华，"刘易斯兰茨伯格学院院长兼医学事务副校长埃里克·G·尼尔森 博士说道。"她是一位杰出的科学家，她在实验室的职业生涯对全球人类健康产生了深远的影响，我们很荣幸授予她2026年金伯利 奖。" 金伯利奖设立于2023年，由金伯利·奎里（Kimberly Querrey）颁发，以纪念她已故的丈夫、西北大学董事、校友和捐助人卢·辛普森 （Lou Simpson ...

以下文章来源于内分泌早知道 ，作者关注内分泌的 内分泌早知道 . 深度分享内分泌用药经验、病例剖析、指南专业解读并紧跟国内外内分泌领域前沿进展，「每医健」旗下内容平台。 《欧洲预防心脏病学杂志》最新发布的一项重磅研究揭示：降糖明星药物司美格鲁肽在心血管保护方面又添新证。这项涵盖多项临床研 究的荟萃分析显示，该药物不仅能有效控制血糖和减重，更能显著降低患者新发房颤的风险。 值得注意的是，研究数据特别指出，相较于注射剂型，口服司美格鲁肽在预防房颤方面展现出更优异的临床效果。这一发现为2型糖尿 病患者的心血管风险管理提供了新的用药选择。 口服剂型表现亮眼，风险骤降5 2% 亚组分析显示，14mg每日一次的口服司美格鲁肽效果尤为突出，房颤风险降低5 2%。相比之下，1. 0mg/周和2.4mg/周的皮下注射剂型 对新发房颤无显著影响，提示给药方式可能影响疗效。 特定人群获益更明显 - 超重/肥胖患者：房颤风险呈下降趋势（OR=0.80，P=0.06），但未达统计学显著水平。 - 2型糖尿病患者：司美格鲁肽组与对照组相比，房颤风险无显著差异（OR=0.86，P=0.27）。 ▍ 重磅研究：司美格鲁肽降低房颤风险17%， ...

Core Viewpoint - The article discusses the potential benefits of switching from GLP-1 receptor agonists (such as Semaglutide and Dulaglutide) to the GIP/GLP-1 receptor agonist Tirzepatide for better blood sugar control and weight loss in type 2 diabetes patients [7][6]. Group 1: Research Findings - A model was developed to predict the effects of different treatment regimens on blood sugar control and weight loss based on clinical trial data [5]. - The model predicts that switching to Tirzepatide after using Semaglutide or Dulaglutide can lead to further reductions in HbA1c levels and weight loss [6]. - After 66 weeks of switching to Tirzepatide, HbA1c levels are expected to decrease by 1.95% to 2.46%, with weight loss ranging from 6.50 kg to 12.10 kg [6]. Group 2: Comparison of Drugs - Semaglutide and Tirzepatide are both designed for weekly administration, with Semaglutide having a half-life of approximately 165-184 hours and Tirzepatide having a half-life of 116.7 hours [9]. - Tirzepatide, being a dual-target agonist, shows superior weight loss effects compared to Semaglutide [10]. - Semaglutide has drawbacks, including potential weight regain after discontinuation, with patients possibly regaining two-thirds of lost weight within a year [10]. Group 3: Market Dynamics - The GLP-1 market is highly competitive, with major players like Eli Lilly and Novo Nordisk expected to dominate the obesity drug market, potentially capturing 80% of the market share by 2030 [12]. - New combination therapies, such as CagriSema, which combines Semaglutide and Cagrilintide, are being developed to enhance weight loss and blood sugar control [11][12].

以下文章来源于肥胖世界ObesityWorld ，作者欢迎订阅 肥胖世界ObesityWorld . 《肥胖世界》Obesity World - 同步传真肥胖及代谢国际新学术进展，为医学减重临床、教研人员搭建一座与国际接轨的桥梁，「每医健」旗下内容平台。 Lancet Diabetes & Endocrinology发表By-Band-Sleeve研究结果，表明在减重效果、提高生活质量和减少合并症方面，Roux-en-Y胃旁路术、 袖状胃切除术优于可调节胃束带术。Roux-en-Y胃旁路术在减重效果方面又优于袖状胃切除术。 By-Band-Sleeve研究在英国12家医疗中心展开，针对重度肥胖患者，系统比较了Roux-en-Y胃旁路术、袖状胃切除术和可调节胃束带术的临床 疗效与安全性。所有受试者在手术前2至4周均接受了低热量饮食，同时根据个人健康状况，研究团队为部分患者配备了抗血栓药物和抗生素。 三种手术均采用腹腔镜微创方式进行。研究共招募了1346名患者进行随机分组，剔除未实际接受手术及术式交叉的患者后，最终405人接受了 Roux-en-Y胃旁路术，342人接受了袖状胃切除术，383人接受了可调节胃束带术 ...

肥胖世界ObesityWorld . 《肥胖世界》Obesity World - 同步传真肥胖及代谢国际新学术进展，为医学减重临床、教研人员搭建一座与国际接轨的桥梁，「每医健」旗下内容平台。 以下文章来源于肥胖世界ObesityWorld ，作者欢迎订阅 癌症是一种极度消耗身体能量的疾病，晚期患者常常出现严重消瘦，身形如同骷髅。 肿瘤细胞为了不断生长、扩散和转移，需要大量摄入葡萄糖，通过有氧糖酵解来获取能量。因此，直接阻断糖酵解通路、减少肿瘤细胞能量供 应，也是一种治疗思路。 不过，今天要介绍的这种方法更加简单、方便且经济（相较于药物治疗），而且在家中就可以实现。 最近，《自然》杂志发表了瑞典卡罗林斯卡学院华人科学家曹义海教授团队的一项最新研究：通过低温刺激，可以激活体内棕色脂肪细胞，加 快能量消耗和产热，与肿瘤细胞"争夺"葡萄糖资源，让肿瘤细胞因"缺糖"而受限。实验显示，这一方法不仅能够抑制多种肿瘤的生长，还能延 长患癌小鼠的生存时间。在人体试验中，22℃的低温疗法同样展现出良好的治疗潜力。 此外，如果在低温治疗期间，给肿瘤小鼠额外补充15%的葡萄糖溶液，尽管棕色脂肪仍会持续大量消耗葡萄糖，但当体内葡萄糖过 ...

整理 | GLP1减重宝典内容团队 最近对 STEP 计划的五项随机对照试验进行的分析发现， 使用司美格鲁肽治疗肥胖的成年人比使用安慰剂的成年人更有可能减少或停 止使用抗高血压和降脂药物 。值得注意的是，两组之间的药物调整存在显著差异，司美格鲁肽使用者的减少幅度更大。 该研究结果于 2025 年 1 月 5 日在线发表在《肥胖》上，研究人员指出，司美格鲁肽是一种胰高血糖素样肽-1 (GLP-1) 受体激动剂，广 泛用于体重管理，并与多种代谢参数的改善有关。观察到的抗高血压和降脂药物使用量的减少与体重显着减轻对血压和血脂状况的已知 影响相一致。他们建议，通过促进治疗强度降低或停药，司美格鲁肽可能为患有肥胖相关心脏代谢疾病的个体简化用药方案提供额外的 优势。 基于上述背景，Beverly G. Tchang 及其同事旨在评估接受司美格鲁肽 2.4 毫克治疗的参与者与接受安慰剂治疗的参与者相比，抗高血 压和降脂治疗的变化。他们分析了五项司美格鲁肽对肥胖人群的治疗效果 (STEP) 试验的汇总数据。 为此，研究人员评估了司美格鲁肽 2.4 毫克在 STEP 临床试验中的疗效和安全性。在这项事后分析中，STEP 1、3 ...